Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
about
Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot studyValidity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study.Assessing the criterion validity of four highly abbreviated measures from the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS).Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) and performance of everyday life tasks: Actual Reality.Clinical outcome measures for progressive MS trials.Repeated Assessment and Practice Effects of the Written Symbol Digit Modalities Test Using a Short Inter-Test Interval.Cognition During and After Multiple Sclerosis Relapse as Assessed With the Brief International Cognitive Assessment for Multiple Sclerosis.
P2860
Q33584623-2C92AFEC-EAFD-4DA1-9B98-EA2C8949A2D4Q33605353-A68C0035-FB1B-475B-8815-0A92E78C5D76Q35672483-F27630BC-E9AE-401A-AE70-701879548871Q38736551-C13A1791-4135-4C14-955C-75AD8CE42D13Q39487647-8C1A43C0-39BF-4A90-8538-15F20D123150Q39698060-9AC7EADC-2C87-45A2-9A06-A1F21613B4E9Q47673261-0F9C29AD-3714-4B4E-8F28-B4A4FB059E14Q47892293-CEC09B9C-F9D6-4EDA-B805-7BAD3DDFD944Q48668774-5BF64F4C-471A-4043-B9C5-AFA8C8991E1EQ55357380-2AD058A0-90FB-4C98-8B99-C1D0405FADFB
P2860
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
@en
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
@nl
type
label
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
@en
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
@nl
prefLabel
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
@en
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
@nl
P2093
P1476
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
@en
P2093
David M Erlanger
Diego Cadavid
Jeffrey Wilken
John Deluca
Lauren S Caruso
Ralph H B Benedict
Tanya Kaushik
P304
P356
10.1016/J.JNS.2014.03.009
P577
2014-03-11T00:00:00Z